Artículos por temáticas

Recent Advances in the Treatment of Huntington's Disease: Targeting DNA and RNA.

Shannon KM.

CNS Drugs. 2020 Jan 13. doi: 10.1007/s40263-019-00695-3. [Epub ahead of print] Review.

Mitochondrial fission in Huntington's disease mouse striatum disrupts ER-mitochondria contacts leading to disturbances in Ca(2+) efflux and Reactive Oxygen Species (ROS) homeostasis.

Cherubini M, Lopez-Molina L, Gines S.

Neurobiol Dis. 2020 Mar;136:104741. doi: 10.1016/j.nbd.2020.104741. Epub 2020 Jan 10.

Early-Motor Phenotype Relates to Neuropsychiatric and Cognitive Disorders in Huntington's Disease

Julayanont P, Heilman KM, McFarland NR.

Mov Disord. 2020 May;35(5):781-788. doi: 10.1002/mds.27980. Epub 2020 Jan 10.

Bioinformatics analysis of the molecular mechanism underlying Huntington's disease.

Wang Z, Dong X, Cong S.

J Integr Neurosci. 2019 Dec 30;18(4):369-376. doi: 10.31083/j.jin.2019.04.1176.

Elevated Type 1 Metabotropic Glutamate Receptor Availability in a Mouse Model of Huntington's Disease: a Longitudinal PET Study.

Bertoglio D, Verhaeghe J, Korat Š, Miranda A, Cybulska K, Wyffels L, Stroobants S, Mrzljak L, Dominguez C, Skinbjerg M, Liu L, Munoz-Sanjuan I, Staelens S.

Mol Neurobiol. 2020 Jan 8. doi: 10.1007/s12035-019-01866-5. [Epub ahead of print]

The effects of dual-task cognitive interference on gait and turning in Huntington's disease.

Purcell NL, Goldman JG, Ouyang B, Liu Y, Bernard B, O'Keefe JA.

PLoS One. 2020 Jan 7;15(1):e0226827. doi: 10.1371/journal.pone.0226827. eCollection 2020.

Structural brain correlates of irritability and aggression in early manifest Huntington's disease

Martinez-Horta S, Sampedro F, Horta-Barba A, Perez-Perez J, Pagonabarraga J, Gomez-Anson B, Kulisevsky J.

Brain Imaging Behav. 2021 Feb;15(1):107-113. doi: 10.1007/s11682-019-00237-x.

Economic burden of Huntington's disease in Peru.

Silva-Paredes G, Urbanos-Garrido RM, Inca-Martinez M, Rabinowitz D, Cornejo-Olivas MR.

BMC Health Serv Res. 2019 Dec 30;19(1):1017. doi: 10.1186/s12913-019-4806-6.

Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme.

Tejeda GS, Whiteley EL, Deeb TZ, Bürli RW, Moss SJ, Sheridan E, Brandon NJ, Baillie GS.

Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):677-688. doi: 10.1073/pnas.1916398117. Epub 2019 Dec 23.

Efficacy of Cholesterol Nose-to-Brain Delivery for Brain Targeting in Huntington's Disease.

Passoni A, Favagrossa M, Colombo L, Bagnati R, Gobbi M, Diomede L, Birolini G, Di Paolo E, Valenza M, Cattaneo E, Salmona M.

ACS Chem Neurosci. 2020 Feb 5;11(3):367-372. doi: 10.1021/acschemneuro.9b00581. Epub 2020 Jan 7.

Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease.

Crapser JD, Ochaba J, Soni N, Reidling JC, Thompson LM, Green KN.

Brain. 2020 Jan 1;143(1):266-288. doi: 10.1093/brain/awz363.

Bim contributes to the progression of Huntington's disease-associated phenotypes.

Roberts SL, Evans T, Yang Y, Fu Y, Button RW, Sipthorpe RJ, Cowan K, Valionyte E, Anichtchik O, Li H, Lu B, Luo S.

Hum Mol Genet. 2020 Jan 15;29(2):216-227. doi: 10.1093/hmg/ddz275.

The interplay between redox signalling and proteostasis in neurodegeneration: In vivo effects of a mitochondria-targeted antioxidant in Huntington's disease mice.

Pinho BR, Duarte AI, Canas PM, Moreira PI, Murphy MP, Oliveira JMA.

Free Radic Biol Med. 2020 Jan;146:372-382. doi: 10.1016/j.freeradbiomed.2019.11.021. Epub 2019 Nov 18.

Brain compensation during visuospatial working memory in premanifest Huntington's disease.

Soloveva MV, Jamadar SD, Velakoulis D, Poudel G, Georgiou-Karistianis N.

Neuropsychologia. 2020 Jan;136:107262. doi: 10.1016/j.neuropsychologia.2019.107262. Epub 2019 Nov 14.

Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.

Sayed NH, Fathy N, Kortam MA, Rabie MA, Mohamed AF, Kamel AS.

Neurotherapeutics. 2020 Jan;17(1):252-268. doi: 10.1007/s13311-019-00805-5.